PHC-HOLDINGS
3.9.2021 12:41:06 CEST | Business Wire | Press release
PHC Holdings Corporation (headquarters: Minato-ku, Tokyo, Japan, President & CEO: John Marotta, hereafter PHCHD), a leading global life science, diagnostics and medical device company, has today announced the appointment of William (Bill) Donnelly and Ivan Tornos as independent external directors, effective September 3, 2021. Both bring significant expertise and executive-level experience at global medical device and life sciences companies.
Mr. Donnelly joins the board with almost 25 years’ experience in the laboratory equipment industry. Mr. Donnelly was most recently the Executive Vice President responsible for Finance, Supply Chain, Manufacturing and IT for Mettler-Toledo. Prior to becoming Executive Vice President, he held various senior executive positions, including Group CFO and as a Global Business Leader for one of Mettler-Toledo’s Divisions. Prior to this he was Chief Financial Officer at Elsag Bailey Process Automation, a market leader in industrial instrumentation and systems for the process control industry. He started his career working as an auditor for Price Waterhouse for 10 years. He is currently an Independent Director of Ingersoll Rand and PST, as well as the Board Chair for John Carroll University.
Mr. Tornos joins the board with almost 25 years’ experience in the medical device industry. Mr. Tornos is currently the Chief Operating Officer at Zimmer Biomet, responsible for overseeing all global businesses and leading the global operations, clinical and medical education, and global R&D functions. Mr. Tornos joined Zimmer Biomet in 2018 as Group President, Orthopedics and was later Group President, Global Businesses and the Americas, before becoming COO earlier this year. Prior to joining Zimmer Biomet, Mr. Tornos was Worldwide President of the Global Urology Group, Medical, and Critical Care Divisions at Becton Dickinson Interventional. He has also held global senior leadership positions in commercial, business development and operations for Covidien International, Baxter International, Johnson & Johnson and Bausch & Lomb.
John Marotta, President, CEO and Chairman of the Board of Directors for PHCHD said, "I am thrilled to have Bill and Ivan join the PHC Holdings Board of Directors. These are two exceptional industry leaders who will add vast experience and capabilities to our board. We are a global company and have set out to add individuals to our board who have deep expertise and diverse perspectives that can help with all aspects of our business. Bill and Ivan’s industry knowledge and strategic guidance will be immensely valuable to the future success of the PHC Group."
Hiro Hirano, Co-Head of Private Equity for KKR Asia and CEO of KKR Japan Limited, and member of the Board of Directors for PHCHD, added, “We are excited about the addition of Bill and Ivan to the PHC Holdings Board of Directors. We have worked to assemble a board with a range of experiences in operational and financial disciplines, and these additions take the board a key step forward in expanding our capabilities. We believe we have the right mix of global leaders who can support the next chapter in the evolution of our business.”
The addition of these new independent external directors follows the recent appointment of Mr. Alan Malus and Ms. Kyoko (Kay) Deguchi in July 2021.
John Marotta added, "Diversity is a high priority for PHC Holdings and all of our operating companies. As we continue to evolve in our journey of diversity and inclusion, we will further evolve our Board of Directors as a part of this initiative.”
About PHC Holdings Corporation
PHC Holdings Corporation is a global healthcare company with subsidiaries including PHC Corporation, Ascensia Diabetes Care, Epredia, and LSI Medience Corporation. Committed to its corporate mission that states, “We contribute to the health of society through our diligent efforts to create healthcare solutions that have a positive impact and improve the lives of people,” the company develops, manufactures, sells and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The PHC Group’s consolidated net sales in FY2020 were 306 billion yen with global distribution of products and services in more than 125 countries.
www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005161/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom